tirzepatide and heart failure Reaching the SUMMIT? Benefits potential risks associated with the use of in with preserved ejection fraction Positive heart failure trial results!

A phase 1 trial included 4 ROR1 -positive TNBC patients who had undergone at least three-line treatments and received ROR1 -targeted CAR-T therapy, 2 individuals showed stable disease, and one participant had a partial response after the second infusion, persisting for 14 weeks

Overall tolerability of the treatment was good, with the most common side effect being nausea, particularly during treatment initiation or dose adjustments, while diarrhea was reported by 5% of patients, which was dose-dependent and easily managed

Neuropsychopharmacology , 40(9), 1963-1973

, , ,

It is the degree of neurobiological adaptation and the structure of behavioral scaffolding built during treatment

The titration approach handles this naturally